Amer M Zeidan

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 38

Top Topics

Acute Myeloid Leukemia

Left Ventricular

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

Annals of hematology

Future oncology (London, England)

Therapeutic advances in hematology

JCO global oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Cristina Astrid Tentori, Caterina Gregorio, Marie Robin, Nico Gagelmann, Carmelo Gurnari, Somedeb Ball, Juan Carlos Caballero-Berrocal, Luca Lanino, Saverio D'Amico, Marta Spreafico, Giulia Maggioni, Erica Travaglino, Elisabetta Sauta, Manja Meggendorfer, Lin-Pierre Zhao, Alessia Campagna, null null, Victor Savevski, Armando Santoro, Najla Al Ali, David A Sallman, Francisco Solé, Guillermo Garcia Manero, Ulrich Germing, Nicolaus Kröger, Shahram Kordasti, Valeria Santini, Guillermo F Sanz, Wolfgang Kern, Uwe Platzbecker, Maria Diez Campelo, Jaroslaw P Maciejewski, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Amer M Zeidan, Gastone C Castellani, Rami S Komrokji, Francesca Ieva, Matteo Giovanni Della Porta, null null
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (24) (2024)
Amer M Zeidan, Kate Perepezko, Tehseen Salimi, Terri Washington, Robert S Epstein
Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms. Therapeutic advances in hematology 15 (2024)
Amer M Zeidan, Jan Philipp Bewersdorf, Vanessa Hasle, Rory Michael Shallis, Ethan Thompson, Daniel Lopes de Menezes, Shelonidta Rose, Isaac Boss, Stephanie Halene, Torsten Haferlach, Brian A Fox
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine. Therapeutic advances in hematology 15 (2024)
Amer M Zeidan, Jan Philipp Bewersdorf, Vanessa Hasle, Rory Michael Shallis, Ethan Thompson, Daniel Lopes de Menezes, Shelonidta Rose, Isaac Boss, Stephanie Halene, Torsten Haferlach, Brian A Fox
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine. Therapeutic advances in hematology 15 (2024)
Amer M Zeidan, Kate Perepezko, Tehseen Salimi, Terri Washington, Robert S Epstein
Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms. Therapeutic advances in hematology 15 (2024)
Tinatin Muradashvili, Yuxin Liu, Jennifer VanOudenhove, Sean X Gu, Diane S Krause, Francesca Montanari, Maximillian J Carlino, Rubia Mancuso, Jessica M Stempel, Stephanie Halene, Amer M Zeidan, Nikolai A Podoltsev, Natalia Neparidze
Aplastic anemia in association with multiple myeloma: clinical and pathophysiological insights. Leukemia & lymphoma (2024)
Abdalla Awidi, Marah Alzu'bi, Nada Odeh, Jawad Alrawabdeh, Muntaser Alzyoud, Yazan Hamadneh, Hisham Bawa'neh, Ahmad Magableh, Alaa Alshorman, Feras Al-Fararjeh, Tariq Aladily, Amer M Zeidan
Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country. JCO global oncology 10 (2024)
Abdalla Awidi, Marah Alzu'bi, Nada Odeh, Jawad Alrawabdeh, Muntaser Alzyoud, Yazan Hamadneh, Hisham Bawa'neh, Ahmad Magableh, Alaa Alshorman, Feras Al-Fararjeh, Tariq Aladily, Amer M Zeidan
Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country. JCO global oncology 10 (2024)
Amer M Zeidan, Jan Philipp Bewersdorf, Vanessa Hasle, Rory Michael Shallis, Ethan Thompson, Daniel Lopes de Menezes, Shelonidta Rose, Isaac Boss, Stephanie Halene, Torsten Haferlach, Brian A Fox
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine. Therapeutic advances in hematology 15 (2024)
Abdalla Awidi, Marah Alzu'bi, Nada Odeh, Jawad Alrawabdeh, Muntaser Alzyoud, Yazan Hamadneh, Hisham Bawa'neh, Ahmad Magableh, Alaa Alshorman, Feras Al-Fararjeh, Tariq Aladily, Amer M Zeidan
Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country. JCO global oncology 10 (2024)
Cristina Astrid Tentori, Caterina Gregorio, Marie Robin, Nico Gagelmann, Carmelo Gurnari, Somedeb Ball, Juan Carlos Caballero-Berrocal, Luca Lanino, Saverio D'Amico, Marta Spreafico, Giulia Maggioni, Erica Travaglino, Elisabetta Sauta, Manja Meggendorfer, Lin-Pierre Zhao, Alessia Campagna, null null, Victor Savevski, Armando Santoro, Najla Al Ali, David A Sallman, Francisco Solé, Guillermo Garcia Manero, Ulrich Germing, Nicolaus Kröger, Shahram Kordasti, Valeria Santini, Guillermo F Sanz, Wolfgang Kern, Uwe Platzbecker, Maria Diez Campelo, Jaroslaw P Maciejewski, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Amer M Zeidan, Gastone C Castellani, Rami S Komrokji, Francesca Ieva, Matteo Giovanni Della Porta, null null
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (24) (2024)
Cristina Astrid Tentori, Caterina Gregorio, Marie Robin, Nico Gagelmann, Carmelo Gurnari, Somedeb Ball, Juan Carlos Caballero-Berrocal, Luca Lanino, Saverio D'Amico, Marta Spreafico, Giulia Maggioni, Erica Travaglino, Elisabetta Sauta, Manja Meggendorfer, Lin-Pierre Zhao, Alessia Campagna, null null, Victor Savevski, Armando Santoro, Najla Al Ali, David A Sallman, Francisco Solé, Guillermo Garcia Manero, Ulrich Germing, Nicolaus Kröger, Shahram Kordasti, Valeria Santini, Guillermo F Sanz, Wolfgang Kern, Uwe Platzbecker, Maria Diez Campelo, Jaroslaw P Maciejewski, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Amer M Zeidan, Gastone C Castellani, Rami S Komrokji, Francesca Ieva, Matteo Giovanni Della Porta, null null
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (24) (2024)
Cristina Astrid Tentori, Caterina Gregorio, Marie Robin, Nico Gagelmann, Carmelo Gurnari, Somedeb Ball, Juan Carlos Caballero-Berrocal, Luca Lanino, Saverio D'Amico, Marta Spreafico, Giulia Maggioni, Erica Travaglino, Elisabetta Sauta, Manja Meggendorfer, Lin-Pierre Zhao, Alessia Campagna, null null, Victor Savevski, Armando Santoro, Najla Al Ali, David A Sallman, Francisco Solé, Guillermo Garcia Manero, Ulrich Germing, Nicolaus Kröger, Shahram Kordasti, Valeria Santini, Guillermo F Sanz, Wolfgang Kern, Uwe Platzbecker, Maria Diez Campelo, Jaroslaw P Maciejewski, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Amer M Zeidan, Gastone C Castellani, Rami S Komrokji, Francesca Ieva, Matteo Giovanni Della Porta
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Abdalla Awidi, Marah Alzu'bi, Nada Odeh, Jawad Alrawabdeh, Muntaser Alzyoud, Yazan Hamadneh, Hisham Bawa'neh, Ahmad Magableh, Alaa Alshorman, Feras Al-Fararjeh, Tariq Aladily, Amer M Zeidan
Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country. JCO global oncology 10 (2024)
Mikkael A Sekeres, Nina Kim, Amy E DeZern, Kelly J Norsworthy, Jacqueline S Garcia, R Angelo de Claro, Marc R Theoret, Emily Y Jen, Lori A Ehrlich, Amer M Zeidan, Rami S Komrokji
Considerations for Drug Development in Myelodysplastic Syndromes. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Amer M Zeidan, Daniel A Pollyea, Uma Borate, Alberto Vasconcelos, Ravi Potluri, David Rotter, Zephirin Kiendrebeogo, Lona Gaugler, Thomas Prebet, Maria Strocchia, Gaetano Bonifacio, Clara Chen
Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. Annals of hematology (2023)
Amer M Zeidan, Daniel A Pollyea, Uma Borate, Alberto Vasconcelos, Ravi Potluri, David Rotter, Zephirin Kiendrebeogo, Lona Gaugler, Thomas Prebet, Maria Strocchia, Gaetano Bonifacio, Clara Chen
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. Annals of hematology 102 (4) (2023)
Peter J P Croucher, Maya Ridinger, Pamela S Becker, Tara L Lin, Sandra L Silberman, Eunice S Wang, Amer M Zeidan
Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Annals of hematology (2023)
Amer M Zeidan, Aristoteles Giagounidis, Mikkael A Sekeres, Zhijian Xiao, Guillermo F Sanz, Marlies Van Hoef, Fei Ma, Sabine Hertle, Valeria Santini
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future oncology (London, England) (2023)
Amer M Zeidan, Daniel A Pollyea, Uma Borate, Alberto Vasconcelos, Ravi Potluri, David Rotter, Zephirin Kiendrebeogo, Lona Gaugler, Thomas Prebet, Maria Strocchia, Gaetano Bonifacio, Clara Chen
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. Annals of hematology 102 (4) (2023)
Amer M Zeidan, Daniel A Pollyea, Uma Borate, Alberto Vasconcelos, Ravi Potluri, David Rotter, Zephirin Kiendrebeogo, Lona Gaugler, Thomas Prebet, Maria Strocchia, Gaetano Bonifacio, Clara Chen
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. Annals of hematology 102 (4) (2023)
Talha Badar, Yazan F Madanat, Amer M Zeidan
Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms. Future oncology (London, England) (2023)
Amer M Zeidan, Aristoteles Giagounidis, Mikkael A Sekeres, Zhijian Xiao, Guillermo F Sanz, Marlies Van Hoef, Fei Ma, Sabine Hertle, Valeria Santini
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future oncology (London, England) (2023)
Amer M Zeidan, Aristoteles Giagounidis, Mikkael A Sekeres, Zhijian Xiao, Guillermo F Sanz, Marlies Van Hoef, Fei Ma, Sabine Hertle, Valeria Santini
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future oncology (London, England) (2023)
Amer M Zeidan, Aristoteles Giagounidis, Mikkael A Sekeres, Zhijian Xiao, Guillermo F Sanz, Marlies Van Hoef, Fei Ma, Sabine Hertle, Valeria Santini
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future oncology (London, England) 19 (9) (2023)
Amer M Zeidan, Aristoteles Giagounidis, Mikkael A Sekeres, Zhijian Xiao, Guillermo F Sanz, Marlies Van Hoef, Fei Ma, Sabine Hertle, Valeria Santini
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future oncology (London, England) (2023)
Amer M Zeidan, Aristoteles Giagounidis, Mikkael A Sekeres, Zhijian Xiao, Guillermo F Sanz, Marlies Van Hoef, Fei Ma, Sabine Hertle, Valeria Santini
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future oncology (London, England) 19 (9) (2023)
Amer M Zeidan, Daniel A Pollyea, Uma Borate, Alberto Vasconcelos, Ravi Potluri, David Rotter, Zephirin Kiendrebeogo, Lona Gaugler, Thomas Prebet, Maria Strocchia, Gaetano Bonifacio, Clara Chen
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. Annals of hematology (2023)
Amer M Zeidan, Aristoteles Giagounidis, Mikkael A Sekeres, Zhijian Xiao, Guillermo F Sanz, Marlies Van Hoef, Fei Ma, Sabine Hertle, Valeria Santini
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future oncology (London, England) 19 (9) (2023)
Rory Michael Shallis, Naval G Daver, Jessica K Altman, Robert P Hasserjian, Hagop M Kantarjian, Uwe Platzbecker, Valeria Santini, Andrew H Wei, David A Sallman, Amer M Zeidan
TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity. Cancer (2022)
Carmelo Gurnari, Zhuoer Xie, Amer M Zeidan
How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms. Clinical hematology international (2022)
Jan Philipp Bewersdorf, Amer M Zeidan
Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes. Cancer 126 (21) (2020)
Amer M Zeidan, Maya Ridinger, Tara L Lin, Pamela S Becker, Gary J Schiller, Prapti A Patel, Alexander I Spira, Michaela L Tsai, Errin Samuëlsz, Sandra L Silberman, Mark Erlander, Eunice S Wang
A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (23) (2020)
Amer M Zeidan, Smith Giri, Michelle DeVeaux, Samir K Ballas, Vu H Duong
Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes. Annals of hematology 98 (2) (2018)
Rory M Shallis, Mina L Xu, Nikolai A Podoltsev, Susanna A Curtis, Bryden T Considine, Suchin R Khanna, Alexa J Siddon, Amer M Zeidan
Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice. Annals of hematology 97 (12) (2018)
Amer M Zeidan, Jessica B Long, Rong Wang, Xin Hu, James B Yu, Scott F Huntington, Gregory A Abel, Sarah S Mougalian, Nikolai A Podoltsev, Steven D Gore, Cary P Gross, Xiaomei Ma, Amy J Davidoff
Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. PloS one 12 (9) (2017)
Amer M Zeidan, Maximilian Stahl, Xin Hu, Rong Wang, Scott F Huntington, Nikolai A Podoltsev, Steven D Gore, Xiaomei Ma, Amy J Davidoff
Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood 131 (7) (2017)
Maliha Khan, Anum Wasim, Aibek E Mirrakhimov, Blaithin A McMahon, Daniel P Judge, Linda C Chu, Ashtami Banavali, Amer M Zeidan
Case report of a patient with left ventricular assistance device undergoing chemotherapy for a new diagnosis of lung cancer. Case reports in oncological medicine 2015 (2015)